Royalty Pharma PLC (RPRX)
NASDAQ:RPRX
Want to see RPRX full AI Analyst Report?
RPRX Stock Chart & Stats
$50.00
$0.10(0.38%)
At close: 4:00 PM EST
$50.00
$0.10(0.38%)
Day’s Range― - ―
52-Week Range$32.15 - $53.47
Previous CloseN/A
Volume726.99K
Average Volume (3M)3.29M
Market Cap
$29.99B
Enterprise Value$30.91B
Total Cash (Recent Filing)$608.29M
Total Debt (Recent Filing)$8.96B
Price to Earnings (P/E)17.6
Beta0.20
Next Earnings
Aug 12, 2026EPS Estimate
1.28Next Dividend Ex-DateN/A
Dividend Yield2.23%
Share Statistics
EPS (TTM)2.46
Shares Outstanding443,274,100
10 Day Avg. Volume4,027,400
30 Day Avg. Volume3,290,996
Financial Highlights & Ratios
PEG Ratio1.01
Price to Book (P/B)2.58
Price to Sales (P/S)7.02
P/FCF Ratio6.70
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue12.67
Enterprise Value/Gross Profit12.67
Enterprise Value/Ebitda17.47
Forecast
1Y Price Target
$59.43Price Target Upside18.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)5.13
Revenue Forecast (FY)$3.46B
Bulls Say, Bears Say
Bulls Say
Capital Structure And DealmakingAn open-ended funding structure and relatively low cost of capital enable the company to outbid rivals for attractive royalty transactions and scale its portfolio.
Clinical And Regulatory CatalystsA broad set of late-stage partnered drugs with planned clinical readouts and regulatory decisions can materially increase future royalty receipts if approvals and launches succeed.
Royalty PortfolioExclusive royalties on leading drugs create a durable competitive advantage that competitors cannot replicate and help secure steady royalty income.
Bears Say
Investor SentimentA persistent unresolved disagreement over royalties undermines investor confidence and may pressure the stock as uncertainty around cash flows remains.
Royalty DisputeAn ongoing royalty dispute represents a material legal overhang that could delay or reduce expected royalty payments until resolved.
Royalty Pharma News
RPRX FAQ
What was Royalty Pharma PLC’s price range in the past 12 months?
Royalty Pharma PLC lowest stock price was $32.15 and its highest was $53.47 in the past 12 months.
What is Royalty Pharma PLC’s market cap?
Royalty Pharma PLC’s market cap is $29.99B.
When is Royalty Pharma PLC’s upcoming earnings report date?
Royalty Pharma PLC’s upcoming earnings report date is Aug 12, 2026 which is in 84 days.
How were Royalty Pharma PLC’s earnings last quarter?
Royalty Pharma PLC released its earnings results on May 06, 2026. The company reported $1.296 earnings per share for the quarter, beating the consensus estimate of $1.214 by $0.082.
Is Royalty Pharma PLC overvalued?
According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued.
Does Royalty Pharma PLC pay dividends?
Royalty Pharma PLC pays a Quarterly dividend of $0.22 which represents an annual dividend yield of 2.23%. See more information on Royalty Pharma PLC dividends here
What is Royalty Pharma PLC’s EPS estimate?
Royalty Pharma PLC’s EPS estimate is 1.28.
How many shares outstanding does Royalty Pharma PLC have?
Royalty Pharma PLC has 443,274,100 shares outstanding.
What happened to Royalty Pharma PLC’s price movement after its last earnings report?
Royalty Pharma PLC reported an EPS of $1.296 in its last earnings report, beating expectations of $1.214. Following the earnings report the stock price went up 0.554%.
Which hedge fund is a major shareholder of Royalty Pharma PLC?
Currently, no hedge funds are holding shares in RPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Royalty Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.43 (18.86% Upside)
$59.43 (18.86% Upside)
Blogger Sentiment
Bullish
RPRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 79.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.30%
12-Months-Change
Fundamentals
Return on Equity
12.67%
Trailing 12-Months
Asset Growth
12.53%
Trailing 12-Months
Company Description
Royalty Pharma PLC
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
RPRX Company Deck
RPRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive: Royalty Pharma reported double-digit recurring revenue growth, attractive returns (ROIC ~14.1%, ROIE ~19.7%), robust cash generation ($722M portfolio cash flow), active capital deployment (>$0.5B) and strategic deal flow including R&D co-funding momentum (J&J and Teva deals) and high-impact clinical/regulatory wins (daraxonrasib, Avlayah, Myqorzo). Key risks highlighted were a material decline in milestone receipts (~53% drop), elevated interest expense timing, some market/policy headwinds (Promacta LOE, biosimilar Tysabri, MFN uncertainty) and optionality/execution risk in future co-funding tranches. Overall, the positive operating and balance-sheet trends and raised guidance outweigh the limited but meaningful risks discussed.View all RPRX earnings summariesRPRX Revenue Breakdown
93.34% Income from financial royalty assets
6.62% Other royalty income
0.04% Revenue from intangible royalty assets
RPRX Stock 12 Month Forecast
Average Price Target
$59.43
▲(18.86% Upside)
Technical Analysis
Ownership Overview
1.57% Insiders
18.46% Mutual Funds
31.11% Other Institutional Investors
38.68% Public Companies and
Individual Investors